See more : Immersion Corporation (IMMR) Income Statement Analysis – Financial Results
Complete financial analysis of Assertio Holdings, Inc. (ASRT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Assertio Holdings, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Meteoric Resources NL (MEI.AX) Income Statement Analysis – Financial Results
- Eastnine AB (publ) (EAST.ST) Income Statement Analysis – Financial Results
- Hastings Technology Metals Limited (AUG.AX) Income Statement Analysis – Financial Results
- BC Craft Supply Co. Ltd. (CRFT.CN) Income Statement Analysis – Financial Results
- First Community Bankshares, Inc. (FCBC) Income Statement Analysis – Financial Results
Assertio Holdings, Inc. (ASRT)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.assertiotx.com
About Assertio Holdings, Inc.
Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 152.07M | 156.23M | 111.01M | 106.28M | 229.50M | 311.77M | 380.72M | 455.90M | 342.74M | 390.36M | 134.21M | 90.82M | 132.97M | 80.76M | 57.73M | 34.84M | 65.58M | 9.55M | 4.41M | 202.57K | 981.99K | 1.66M | 3.67M | 1.78M | 115.33K | 800.00K | 600.00K | 300.00K |
| Cost of Revenue | 27.02M | 18.75M | 15.83M | 19.87M | 9.51M | 18.48M | 72.60M | 87.41M | 67.90M | 15.15M | 7.09M | 6.04M | 5.54M | 8.10M | 5.26M | 5.77M | 2.60M | 1.60M | 908.52K | 0.00 | 0.00 | 0.00 | 0.00 | -561.76K | -643.49K | -500.00K | -200.00K | 0.00 |
| Gross Profit | 125.05M | 137.49M | 95.18M | 86.40M | 220.00M | 293.29M | 308.13M | 368.48M | 274.84M | 375.22M | 127.11M | 84.78M | 127.43M | 72.67M | 52.47M | 29.07M | 62.99M | 7.95M | 3.50M | 202.57K | 981.99K | 1.66M | 3.67M | 2.34M | 758.82K | 1.30M | 800.00K | 300.00K |
| Gross Profit Ratio | 82.23% | 88.00% | 85.74% | 81.30% | 95.86% | 94.07% | 80.93% | 80.83% | 80.19% | 96.12% | 94.72% | 93.35% | 95.83% | 89.97% | 90.89% | 83.43% | 96.04% | 83.24% | 79.38% | 100.00% | 100.00% | 100.00% | 100.00% | 131.63% | 657.97% | 162.50% | 133.33% | 100.00% |
| Research & Development | 2.84M | 0.00 | 0.00 | 4.21M | 10.11M | 8.04M | 38.62M | 32.63M | 72.44M | 7.12M | 8.07M | 15.46M | 15.19M | 20.11M | 34.30M | 27.27M | 23.34M | 26.89M | 18.37M | 21.36M | 26.90M | 24.71M | 15.46M | 7.49M | 3.73M | 2.10M | 900.00K | 400.00K |
| General & Administrative | 65.34M | 43.39M | 54.76M | 103.92M | 108.07M | 118.42M | 192.00M | 200.40M | 197.05M | 119.33M | 105.18M | 97.65M | 54.21M | 17.51M | 16.66M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 4.40M | 3.40M | 1.80M | 400.00K | 800.00K | 800.00K | 3.70M | 4.10M | 2.30M | 1.80M | 2.40M | 1.50M | 27.34M | 31.42M | 23.59M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 78.64M | 46.79M | 56.56M | 104.32M | 108.87M | 119.22M | 195.70M | 204.50M | 199.35M | 121.13M | 105.18M | 97.65M | 81.54M | 48.93M | 40.25M | 26.40M | 26.69M | 22.67M | 11.64M | 5.18M | 3.48M | 5.37M | 2.53M | 2.03M | 1.87M | 2.00M | 1.00M | 400.00K |
| Other Expenses | 287.10M | 32.61M | 28.11M | 24.78M | 101.77M | 101.77M | 102.75M | 106.85M | 599.00K | 10.16M | -249.00K | 481.00K | 0.00 | 0.00 | 0.00 | -7.50M | -34.58M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 561.76K | 643.49K | 500.00K | 200.00K | 0.00 |
| Operating Expenses | 368.59M | 79.39M | 84.67M | 133.32M | 220.75M | 229.03M | 337.06M | 343.97M | 355.14M | 138.40M | 117.80M | 115.13M | 96.73M | 69.04M | 74.54M | 46.17M | 15.45M | 49.56M | 30.01M | 26.54M | 30.38M | 30.09M | 17.99M | 10.08M | 6.25M | 4.60M | 2.10M | 800.00K |
| Cost & Expenses | 395.61M | 98.14M | 100.50M | 153.19M | 230.25M | 247.51M | 409.66M | 431.39M | 423.04M | 153.55M | 124.89M | 121.17M | 102.28M | 77.14M | 79.80M | 51.94M | 18.04M | 51.16M | 30.92M | 26.54M | 30.38M | 30.09M | 17.99M | 9.51M | 5.61M | 4.10M | 1.90M | 800.00K |
| Interest Income | 0.00 | 7.96M | 10.22M | 15.93M | 58.39M | 1.20M | 681.00K | 485.00K | 599.00K | 215.00K | 662.00K | 520.00K | 557.00K | 839.00K | 1.05M | 2.35M | 2.27M | 2.03M | 1.45M | 489.01K | 299.14K | 101.11K | 0.00 | 222.95K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.38M | 7.96M | 10.22M | 15.93M | 58.39M | 68.88M | 73.55M | 83.72M | 73.44M | 23.92M | 4.49M | 39.00K | 133.00K | 572.00K | 1.00M | 555.00K | 0.00 | 0.00 | 459.74K | 928.88K | 910.42K | 732.57K | 105.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 28.23M | 33.41M | 29.11M | 26.38M | 102.97M | 106.43M | 105.50M | 109.38M | 83.34M | 10.16M | 4.55M | 2.02M | 420.00K | 439.00K | 808.00K | 1.15M | 865.00K | 1.38M | 1.14M | 1.70M | 1.04M | 745.14K | 610.81K | 561.76K | 643.49K | 500.00K | 200.00K | 0.00 |
| EBITDA | -222.45M | 72.54M | 38.78M | -3.20M | -61.12M | 213.16M | 74.05M | 133.76M | 35.94M | 252.64M | 16.68M | -27.27M | 71.68M | 4.90M | -20.21M | -13.60M | 48.40M | -40.23M | -25.37M | -24.63M | -28.35M | -27.68M | -13.71M | -7.18M | -4.85M | -2.84M | -1.00M | -500.00K |
| EBITDA Ratio | -146.28% | 58.38% | 35.88% | -23.86% | 45.74% | 53.64% | 19.57% | 28.92% | 1.06% | 63.32% | 10.15% | -31.20% | -7.00% | 5.53% | -36.42% | -67.30% | 21.07% | -421.17% | -599.99% | -12,160.55% | -2,887.38% | -2,749.98% | -373.25% | -280.87% | 6,215.39% | -412.50% | -183.33% | -166.67% |
| Operating Income | -243.54M | 57.81M | 9.42M | -46.92M | 3.20M | 43.66M | -42.18M | 24.51M | -50.40M | 236.81M | 9.32M | -30.35M | 70.70M | 3.63M | -22.07M | -17.10M | 47.54M | -41.61M | -26.51M | -26.33M | -29.40M | -28.43M | -14.32M | -7.74M | -5.49M | -3.30M | -1.30M | -500.00K |
| Operating Income Ratio | -160.15% | 37.00% | 8.49% | -44.15% | 1.39% | 14.00% | -11.08% | 5.38% | -14.71% | 60.67% | 6.94% | -33.42% | 53.17% | 4.49% | -38.23% | -49.06% | 72.49% | -435.62% | -601.81% | -13,000.40% | -2,993.76% | -1,711.27% | -389.88% | -435.66% | -4,760.78% | -412.50% | -216.67% | -166.67% |
| Total Other Income/Expenses | -10.52M | -26.65M | -9.98M | 36.64M | -28.06M | -5.68M | -61.75M | -89.01M | -72.84M | -23.71M | -4.74M | 481.00K | 424.00K | 267.00K | 49.00K | 1.79M | 39.56M | 2.03M | 2.04M | -439.87K | -5.36K | 15.56M | -3.17M | -2.19M | -12.02M | 536.86K | 0.00 | 500.00K |
| Income Before Tax | -254.05M | 31.17M | -553.00K | -45.51M | -222.48M | 37.98M | -103.92M | -64.50M | -123.24M | 213.11M | 4.58M | -29.87M | 71.12M | 3.89M | -22.02M | -15.30M | 49.81M | -39.58M | -24.47M | -26.77M | -29.40M | -12.86M | -17.49M | -9.93M | -17.51M | -2.80M | 0.00 | 0.00 |
| Income Before Tax Ratio | -167.06% | 19.95% | -0.50% | -42.83% | -96.94% | 12.18% | -27.30% | -14.15% | -35.96% | 54.59% | 3.41% | -32.89% | 53.49% | 4.82% | -38.15% | -43.92% | 75.95% | -414.36% | -555.40% | -13,217.54% | -2,994.31% | -774.33% | -476.27% | -558.82% | -15,178.98% | -350.00% | 0.00% | 0.00% |
| Income Tax Expense | 77.89M | -78.46M | 728.00K | -17.37M | -5.28M | 1.07M | -1.43M | 24.22M | -47.50M | 81.35M | -38.73M | -91.00K | 396.00K | -4.00K | -15.00K | 1.00K | 592.00K | 82.50K | -2.04M | 99.00K | 611.28K | -17.37M | 105.20K | 1.96M | 11.72M | -500.00K | -100.00K | 500.00K |
| Net Income | -331.94M | 109.63M | -1.28M | -28.14M | -217.20M | 36.91M | -102.50M | -88.72M | -75.74M | 131.76M | 43.31M | -29.78M | 70.73M | 3.90M | -22.01M | -15.30M | 49.22M | -39.66M | -24.47M | -26.87M | -30.02M | -13.49M | -17.60M | -9.70M | -17.21M | -2.80M | -1.20M | -500.00K |
| Net Income Ratio | -218.28% | 70.17% | -1.15% | -26.48% | -94.64% | 11.84% | -26.92% | -19.46% | -22.10% | 33.75% | 32.27% | -32.79% | 53.19% | 4.82% | -38.12% | -43.92% | 75.05% | -415.23% | -555.40% | -13,266.41% | -3,056.56% | -812.35% | -479.13% | -546.27% | -14,921.74% | -350.00% | -200.00% | -166.67% |
| EPS | -4.67 | 2.33 | -0.03 | -1.07 | -12.29 | 2.31 | -6.54 | -5.80 | -5.04 | 9.04 | 3.04 | -2.13 | 5.20 | 0.28 | -1.71 | -1.25 | 4.24 | -3.82 | -2.46 | -3.10 | -4.91 | -3.69 | -6.89 | -5.29 | -10.63 | -1.77 | -1.08 | -0.48 |
| EPS Diluted | -4.67 | 2.01 | -0.03 | -1.07 | -12.29 | 2.30 | -6.54 | -5.79 | -5.04 | 8.20 | 3.00 | -2.13 | 5.04 | 0.28 | -1.71 | -1.25 | 4.20 | -3.82 | -2.46 | -3.10 | -4.91 | -3.69 | -6.89 | -5.29 | -10.63 | -1.77 | -1.08 | -0.48 |
| Weighted Avg Shares Out | 71.03M | 47.00M | 43.17M | 26.21M | 17.68M | 15.95M | 15.68M | 15.30M | 15.03M | 14.57M | 14.18M | 13.97M | 13.64M | 13.13M | 12.88M | 12.19M | 11.49M | 10.38M | 9.96M | 8.66M | 6.11M | 3.66M | 2.56M | 1.83M | 1.62M | 1.58M | 1.11M | 1.04M |
| Weighted Avg Shares Out (Dil) | 71.03M | 54.67M | 43.17M | 26.21M | 17.68M | 16.05M | 15.68M | 15.32M | 15.03M | 16.58M | 14.39M | 13.97M | 14.02M | 13.34M | 12.88M | 12.19M | 11.59M | 10.38M | 9.96M | 8.66M | 6.11M | 3.66M | 2.56M | 1.83M | 1.62M | 1.58M | 1.11M | 1.04M |
New Strong Buy Stocks for November 29th
MKTAY, ASRT, CHH, DRS and BRKL have been added to the Zacks Rank #1 (Strong Buy) List on November 29, 2024.
Buxton Helmsley Calls for Senate Hearing on Well-Documented Evident Clinical Data Fraud at Assertio
NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates, “BHG” or “we”), a New York City-based investment fund manager that recently inverted its long equity position into that of a short interest in the publicly traded...
Assertio Holdings, Inc. (ASRT) Q3 2024 Earnings Call Transcript
Call Start: 16:30 January 1, 0000 5:03 PM ET Assertio Holdings, Inc. (NASDAQ:ASRT ) Q3 2024 Earnings Conference Call November 11, 2024 04:30 PM ET Company Participants Matthew Kreps - Darrow Associates, IR Brendan O'Grady - CEO Ajay Patel -...
Assertio (ASRT) Reports Q3 Loss, Lags Revenue Estimates
Assertio (ASRT) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to earnings of $0.01 per share a year ago.
Assertio Reports Third Quarter 2024 Financial Results
Third Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million Cash and Short-Term Investments of $88.6 Million LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq:...
Buxton Helmsley Releases Evidence of Product-Related Fraud at Assertio
NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates, “BHG” or “we”), a New York City-based investment fund manager that has inverted its long equity position into that of a short interest in the publicly traded...
Assertio Provides Response to Letter from Short-seller
Claims about Rolvedon and Assertio's Accounting Practices are False and Baseless Short-seller's Press Release is Another Improper Attempt to Enrich Himself at Assertio's Expense Company Considering Taking Legal and Regulatory Action LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE) --...
Buxton Helmsley Issues Letter to Assertio Stockholders Disclosing Inversion to Short Position Following Board Refusal to Address Product-Related Fraud
NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates, “BHG” or “we”), a New York City-based investment fund manager that has now inverted its long equity position into that of a short interest in the publicly...
Assertio to Participate in the Maxim Group Healthcare Virtual Summit on October 15, 2024
LAKE FOREST, Ill., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that Brendan O'Grady, Chief Executive Officer, will participate in...
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
LAKE FOREST, Ill., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that effective October 1, 2024, the Compensation Committee of...
Source: https://incomestatements.info
Category: Stock Reports